ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2008) 16 P280

Type 1 iodothyronine deiodinase (D1) enzymatic activity is not reduced in liver focal nodular hyperplasia (FNH)

Anna Szalas1, Marta Stepnowska1, Marcin Debski1, Oskar Kornasiewicz2, Marek Krawczyk2 & Ewa Bar-Andziak1

1Chair and Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland; 2Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

FNH is the second most common benign liver tumor caused mainly by oral contraceptives. D1, which is a crucial enzyme in catalyzing prohormone thyroxine (T4) into active triiodothyronine (T3), is mainly present in such tissues as thyroid, liver and kidney. There are only few data about D1 enzymatic activity in neoplasmatic conditions. Mostly in tumors reduced D1 activity was found.

The aim of the study was to examine the activity of this enzyme in FNH.

Thirteen samples of the tumor and the corresponding number of healthy control tissues were collected from the patients, who underwent the surgery because of that disease. Average age was 28.3. We assessed the activity by measurement of radioactive iodine released in deiodination reaction catalyzed by D1.

We found that D1 enzymatic activity is not reduced in FNH in comparison with healthy controls (P=0.555). Our finding demonstrates that not every type of neoplasm presents low D1 activity.

Article tools

My recent searches

No recent searches.